Dr Habeebullah Life Sciences reports standalone net profit of Rs 1.58 crore in the March 2022 quarter

Dr Habeebullah Life Sciences reports standalone net loss of Rs 0.04 crore in the June 2021 quarter

Dr Habeebullah Life Sciences reports consolidated net loss of Rs 0.04 crore in the June 2021 quarter

Dr Habeebullah Life Sciences reports standalone net loss of Rs 0.02 crore in the March 2021 quarter

Dr Habeebullah Life Sciences reports consolidated net loss of Rs 0.01 crore in the March 2021 quarter

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Dr Habeebullah Life Sciences Ltd is engaged in the business of bio-pharma. It is focused on new drug discovery; clinical research organization related activities; stem cell-lab, research & therapy;  nutraceuticals product development etc.

Dr Habeebullah Life Sciences Ltd

With a market cap of ₹27 cr, stock is ranked 3,023

Dr Habeebullah Life Sciences Ltd

Dr Habeebullah Life Sciences Ltd

Scorecard

News & Opinions

Dr Habeebullah Life Sciences reports standalone net profit of Rs 1.58 crore in the March 2022 quarter

Dr Habeebullah Life Sciences reports standalone net loss of Rs 0.04 crore in the June 2021 quarter

Dr Habeebullah Life Sciences reports consolidated net loss of Rs 0.04 crore in the June 2021 quarter

Dr Habeebullah Life Sciences reports standalone net loss of Rs 0.02 crore in the March 2021 quarter

Dr Habeebullah Life Sciences reports consolidated net loss of Rs 0.01 crore in the March 2021 quarter